{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"440","value":"933"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"To assess the pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status.","dispersionType":"Standard Deviation","groups":[{"description":"Assessment of pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status.","id":"OG000","title":"Part 1 (Pharmacokinetics)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 12 post-dose","title":"Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax","type":"PRIMARY","unitOfMeasure":"Ng/mL"}